EN | TR
E-ISSN: 3061-9947
Data Of Salivary Gland Adenoid Cystic And Muko-Epidermoid Carcınoma Patients
PDF
Cite
Share
Request
Original Article
VOLUME: 53 ISSUE: 1
P: 1-4
2020

Data Of Salivary Gland Adenoid Cystic And Muko-Epidermoid Carcınoma Patients

Acta Haematol Oncol Turc 2020;53(1):1-4
DOI: 10.5505/aot.2020.24008
Fatih Demircioğlu 1
Beyhan Ceylaner Bıçakçı 2
1. S.B.Ü. Dr. Alpaslan Yurtaslan Ankara Oncology Education and Research Hospital, Radiation Oncology, Ankara, Turkey
2. S.B.Ü. Dr. Lütfi Kırdar Kartal Education and Research Hospital, Radiation Oncology, İstanbul, Turkey
3.
No information available.
No information available
Received Date: 2019-12-19T11:46:18
Accepted Date: 2020-04-28T11:02:20
PDF
Cite
Share
Request

Abstract

INTRODUCTION

Salivary gland tumors are a heterogeneous type of cancer with different histological types, accounting for approximately 3-5% of head and neck cancers. Due to this heterogeneity and its incidence, there are no research articles about malignant salivary gland tumors in large series. Therefore, in order to contribute to the literature, the data of our patients with Mucoepidermoid Carcinoma (MEC) and Adenoid Cystic Carcinoma (ACC) were shared in the study.

METHODS

Thirty-seven patients with salivary gland MEC and ACC between July 2007 and December 2018 were included in the study. Pathological diagnoses, tumor localizations, treatments, presence of local recurrence and distant metastasis and survival were evaluated retrospectively and mean data were analyzed.

RESULTS

Of the patients included in the study, 14 were MEC and 23 were ACC. The mean age was 50.15. The mean age of patients with ACC was higher (52.77 - 45.84). Tumor localization of all patients; 16 were parotid, 8 were submandibular, 13 were sublingual and minor salivary glands. Local recurrence was observed in 14.3% of MEC and 13% of ACC patients. Distant metastasis were seen in 7.1% of MEC and 34.8% of ACC patients. The mean survival time was 71.2 months in patients with MEC, and 56.4 months in ACC.

DISCUSSION AND CONCLUSION

The data we obtained in our study were generally consistent with the current literature. It is thought to contribute to the literature data in this rare group of diseases. Multicentre randomized clinical trials are needed for follow-up and treatment standardization.